Elevated osteopontin levels in active relapsing-remitting multiple sclerosis

被引:97
|
作者
Vogt, MHJ
Lopatinskaya, L
Smits, M
Polman, CH
Nagelkerken, L
机构
[1] TNO Prevent & Hlth, Div Infect Dis & Immunol, NL-2301 CE Leiden, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands
关键词
D O I
10.1002/ana.10606
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In the search for proteins that might play a role in the pathogenesis of multiple sclerosis (MS), osteopontin (OPN) has been identified as the most prominent cytokine-encoding gene expressed within MS lesions. Here, we report significantly increased OPN protein levels in plasma of relapsing-remitting MS patients. In contrast, OPN protein levels in primary progressive and secondary progressive MS patients were similar to healthy control levels. Interestingly, active relapsing-remitting patients had higher OPN protein levels than patients without relapses.
引用
收藏
页码:819 / 822
页数:4
相关论文
共 50 条
  • [21] Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
    Kalincik, Tomas
    Horakova, Dana
    Spelman, Tim
    Jokubaitis, Vilija
    Trojano, Maria
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Rozsa, Csilla
    Grammond, Pierre
    Alroughani, Raed
    Duquette, Pierre
    Girard, Marc
    Pucci, Eugenio
    Lechner-Scott, Jeannette
    Slee, Mark
    Fernandez-Bolanos, Ricardo
    Grand'Maison, Francois
    Hupperts, Raymond
    Verheul, Freek
    Hodgkinson, Suzanne
    Oreja-Guevara, Celia
    Spitaleri, Daniele
    Barnett, Michael
    Terzi, Murat
    Bergamaschi, Roberto
    McCombe, Pamela
    Sanchez-Menoyo, Jose
    Simo, Magdolna
    Csepany, Tunde
    Rum, Gabor
    Boz, Cavit
    Havrdova, Eva
    Butzkueven, Helmut
    [J]. ANNALS OF NEUROLOGY, 2015, 77 (03) : 425 - 435
  • [22] Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
    Alroughani, R.
    Al Hashel, J.
    Thussu, A.
    Ahmed, S. F.
    [J]. MEDICAL PRINCIPLES AND PRACTICE, 2013, 22 (05) : 495 - 499
  • [23] Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
    Andersen, O
    Lycke, J
    Tollesson, PO
    Svenningsson, A
    Runmarker, B
    Linde, AS
    Astrom, M
    Gjorstrup, P
    Ekholm, S
    [J]. NEUROLOGY, 1996, 47 (04) : 895 - 900
  • [24] Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection
    Alvarez-Lafuente, R
    De las Héras, V
    Bartolomé, M
    Picazo, JJ
    Arroyo, R
    [J]. ARCHIVES OF NEUROLOGY, 2004, 61 (10) : 1523 - 1527
  • [25] Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis
    Niiranen, Marja
    Kontkanen, Aleksi
    Jaaskelainen, Olli
    Tertsunen, Hanna-Mari
    Selander, Tuomas
    Hartikainen, Paivi
    Huber, Nadine
    Solje, Eino
    Haapasalo, Annakaisa
    Kokkola, Tarja
    Lohioja, Tarja
    Herukka, Sanna-Kaisa
    Simula, Sakari
    Remes, Anne M.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
  • [26] Cladribine TabletsIn Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    [J]. CNS Drugs, 2011, 25 : 239 - 249
  • [27] Metabolomic profiling in relapsing-remitting multiple sclerosis
    Patel, Y.
    Vingara, L.
    Li, Y.
    Yu, H. J.
    Wagshul, M.
    Pelczer, I.
    Christodoulou, C.
    Melville, P.
    Maletic-Savatic, M.
    Krupp, L.
    [J]. MULTIPLE SCLEROSIS, 2009, 15 (09): : S80 - S80
  • [28] Immunomonitoring measures in relapsing-remitting multiple sclerosis
    Matsui, M
    Araya, S
    Wang, HY
    Matsushima, K
    Saida, T
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2004, 148 (1-2) : 192 - 199
  • [29] Oral fumarate for relapsing-remitting multiple sclerosis
    Sorensen, Per Soelberg
    Sellebjerg, Finn
    [J]. LANCET, 2008, 372 (9648): : 1447 - 1448
  • [30] Fatigue in multiple sclerosis relapsing-remitting form
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Felipe, E
    Moreira, MA
    Barao-Cruz, AM
    [J]. ARQUIVOS DE NEURO-PSIQUIATRIA, 2000, 58 (2B) : 471 - 475